著者名,論文名,雑誌名,ISSN,出版者名,出版日付,巻,号,ページ,URL,URL(DOI)
H Miles Prince and Youn H Kim and Steven M Horwitz and Reinhard Dummer and Julia Scarisbrick and Pietro Quaglino and Pier Luigi Zinzani and Pascal Wolter and Jose A Sanches and Pablo L Ortiz-Romero and Oleg E Akilov and Larisa Geskin and Judith Trotman and Kerry Taylor and Stephane Dalle and Michael Weichenthal and Jan Walewski and David Fisher and Brigitte Dréno and Rudolf Stadler and Tatyana Feldman and Timothy M Kuzel and Yinghui Wang and Maria Corinna Palanca-Wessels and Erin Zagadailov and William L Trepicchio and Wenwen Zhang and Hui-Min Lin and Yi Liu and Dirk Huebner and Meredith Little and Sean Whittaker and Madeleine Duvic and David Joske and H. Miles Prince and Ian D. Lewis and Constanze Jonak and Franz Trautinger and Oliver Bechter and Dominique Bron and Vladmir Claudio C. de Lima and Jose Antonio Sanches and Richard Klasa and Martine Bagot and Marie Beylot-Barry and Michel D'Incan and Brigitte Dreno and Florent Grange and Jan Nicolay and Marion Wobser and Chalid Assaf and Carmen Loquai and Michele Spina and Alberto Bosi and Pier Paolo Fattori and Aleksandra Grzanka and Andres Lopez-Hernandez and Pablo L. Ortiz-Romero and Jose Juan Rifon Roca and Silvana Novelli Canales and Timothy Illidge and Rod Johnson and Stephen Morris and Pam McKay and Oleg Akilov and Steve Horwitz and Youn H. Kim and Barbara Pro and Timothy Kuzel and Adam Lerner and Herbert Eradat and Lubomir Sokol and David C. Fisher and Sarah Hughey,"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial",The Lancet,0140-6736,Elsevier BV,2017-08,390,10094,555-566,https://cir.nii.ac.jp/crid/1362825894688558976,https://doi.org/10.1016/s0140-6736(17)31266-7